Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study

Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited representation of subjects with abnormal body weight, which were mostly limited to a BMI > 40 kg/m(2), or body weight > 120 kg for obese subjects, and <50 kg for underweight subjects. Although lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wołowiec, Łukasz, Kusiak, Mateusz, Budzyński, Jacek, Wołowiec, Anna, Jaśniak, Albert, Wiciński, Michał, Pedrycz-Wieczorska, Agnieszka, Rogowicz, Daniel, Grześk, Grzegorz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419712/
https://www.ncbi.nlm.nih.gov/pubmed/37568371
http://dx.doi.org/10.3390/jcm12154969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419712/
https://www.ncbi.nlm.nih.gov/pubmed/37568371
http://dx.doi.org/10.3390/jcm12154969

Ejemplares similares